12 Sep 2008 07:00

|
For immediate release |
12Ā SeptemberĀ 2008 |
ABCAM PLC
("Abcam" or "the Company")
Shareholding
Cambridge UK, 11 September 2008: Abcam plc announces that in accordance with the FSA's Disclosure and Transparency Rules, the Company has been notified that, as at 10 September 2008, Standard Life Investments Limited has a direct interest in voting rights over 426,077 ordinary shares of 1p each in the Company amounting to approximately 1.215% of the issued share capital of the Company and an indirect interest in voting rights over 3,773,621 ordinary shares of 1p each in the Company amounting to approximately 10.761% of the issued share capital of the Company; amounting to a direct and indirect interest of approximately 11.976% of the issued share capital of the Company.
For further information please contact:
|
Abcam |
+ 44 (0) 1223 696000 |
|
Jonathan Milner, Chief Executive Officer |
|
|
Jeff Iliffe, Chief Financial Officer www.abcam.com |
|
|
Numis Securities |
+ 44 (0) 20 7776 1500 |
|
Michael MeadeĀ /Ā Nick WestlakeĀ (Nominated adviser) |
|
|
James BlackĀ (Corporate broking)Ā |
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Mark CourtĀ / Mary-Jane Johnson |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered inĀ Cambridge,Ā UK, with aĀ USĀ office located inĀ Cambridge,Ā MassachusettsĀ and a Japanese office inĀ Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high qualityĀ andĀ commerciallyĀ viable. Abcam now has an online catalogue of approximately 44,000Ā products, most of which are antibodies, from over 250Ā suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employsĀ approximatelyĀ 184Ā staff in its three operating companies.
Follow the stocks